Educational research & price index · Independent Janoshik & MZ Biolabs COA verification
Guide|3 CitationsGLP-1 & Metabolic16-AA vs. 17-AA Blend / Stack

HGH Fragment 176-191 Dosing Protocol: Lipolytic Domain vs. AOD-9604

Also known as: Frag 176-191, hGH(176-191) Lipolytic Peptide, Fragment 176-191 vs. AOD-9604

Dose Range
250–500 mcgResearch range
0Typical research window: 250–500 mcg600 mcg

Studied in published research — not a medical recommendation. Primary protocol (Fasted Lipolytic SubQ Protocol): 250 mcg – 500 mcg (0.25–0.5 mg), 1–2x daily strictly fasted (AM before fasted cardio, optional PM 3+ hrs post-meal).

Protocol at a Glance
How Often
1–2× daily

1–2x daily strictly fasted (AM before fasted cardio, optional PM 3+ hrs post-meal)

A Typical Run
8–12 weeks

Research-reported range; the linked study used a different dose or units. Must be administered in a low-insulin fasted state; elevated post-meal insulin blunts hormone-sensitive lipase activation

How It's Taken
Vial

Subcutaneous injection (abdominal adipose)

Evidence
Clinical Trials

Published peer-reviewed research & clinical protocols

Half-Life & 72-Hour Clearance Shape
Not established

No verified human half-life on file for this compound

0h18h36h54h72h
On Your SyringeU-100 Insulin Syringe

A vial is powder until you add bacteriostatic water. Change the vial size or water volume below to see the exact unit mark on your syringe.

5 mg vial · 2 mL water · 0.3 mL syringe
Concentration: 2.5 mg in every mL (25 mcg per unit)
0u6u12u18u24u30u
Low end: 250 mcg10 units
High end: 500 mcg20 units

All U-100: 100 units = 1 mL. 20 doses in the vial at the low end (10 doses at the high end).

Track the doses you run

Save HGH Fragment 176-191 to your personal protocol list to log your custom dosage, syringe units, ON/OFF cycle dates, and lab notes across devices.

At a Glance · 2026 FDA / 503A / WADA / Evidence Profile

2026 FDA 503A Cat-2 UpdateTier 3 — Translational Animal & Clinical Obs
Pharmacological Class
16-AA C-Terminal Lipolytic Somatropin Fragment (hGH 176–191 · Non-GHR Binding)
Administration Route
Under-the-skin injection (Subcutaneous injection (abdominal adipose))
2026 FDA & 503A Status
Not FDA-approved. In April 2026, the FDA removed 14 peptides (including BPC-157, Thymosin Beta-4/TB-500, CJC-1295, Ipamorelin, AOD-9604, Semax, Selank, and DSIP) from the Category 2 503A Interim Bulks List pending formal July 2026 PCAC rulemaking. Available as COA-verified research reference standards or via specialized physician telehealth guidance.
WADA Sport Status
Strictly Prohibited at All Times — WADA Section S2.2 (Peptide Hormones, Growth Factors, GH Fragments, BPC-157 & Thymosin-β4)
Evidence Tier
Tier 3 — Translational Animal & Clinical Obs: Replicated mammalian preclinical models plus extensive off-label physician & community protocol tracking
What is a Peptide?

A short chain of amino acids (2-50) linked by peptide bonds. Smaller than proteins. Your body produces thousands of peptides naturally as signaling molecules that regulate everything from appetite to healing. Therapeutic peptides mimic or enhance these natural signals.

Bottom Line Up Front

HGH Fragment 176-191 is the synthetic 16-AA C-terminal lipolytic domain of human growth hormone. It stimulates adipocyte beta-3 adrenergic receptors and hormone-sensitive lipase (HSL) without binding the full-length GH receptor, raising IGF-1, or inducing insulin resistance (unlike 17-AA Tyr-modified AOD-9604, it has no added N-terminal tyrosine).

Best evidence for

Fasted lipolysis and anti-lipogenic signaling without IGF-1 or blood glucose elevation

Weakest evidence for

Central appetite suppression (zero satiety effect; requires fasted dosing and caloric control)

Pharma equivalent

None

Studies on file

3 (0 human)

EDUCATIONAL AND RESEARCH REFERENCE ONLY — NOT MEDICAL ADVICE. HGH Fragment 176-191 is not FDA approved for human use (unless specified above). This information does not constitute medical advice.

Overview

While full-length 191-AA somatropin (hGH) stimulates both anabolic IGF-1 production (via residues 1–175) and adipose lipolysis (via the C-terminal disulfide loop at residues 176–191), exogenous hGH can induce insulin resistance and fluid retention. Monash University biochemists discovered that cleaving only residues 176–191 preserves 100% of the hormone’s lipolytic and anti-lipogenic signaling in white adipose tissue while completely eliminating GH receptor binding, IGF-1 elevation, and diabetogenic insulin antagonism.

Mechanisms of Action

  • Up-regulates adipocyte beta-3 adrenergic receptor (β3-AR) expression and hormone-sensitive lipase (HSL) activity to mobilize stored triglycerides
  • Inhibits acetyl-CoA carboxylase to suppress de novo lipogenesis (fatty acid synthesis) in white adipose tissue
  • Zero binding to the full-length transmembrane Growth Hormone Receptor (GHR) and zero effect on serum IGF-1 levels
  • Does not induce hyperinsulinemia or impaired glucose tolerance—unlike exogenous full-length hGH

Common Ratios, Vial Formats & Dosing Breakdown

Researchers use different ratios depending on whether they reconstitute a pre-mixed vial or draw from separate single-compound vials.

Open in Blend Calculator
16-AA vs. 17-AA

HGH Fragment 176-191 (16-AA) vs. AOD-9604 (17-AA Tyr-Stabilized)

Vial / Stack Breakdown

5 mg or 10 mg Lyophilized Vial

Typical Dosing & Syringe Draw

250–500 mcg SubQ fasted AM (30–60 min before fasted cardio/meal)

Why this ratio: Fragment 176-191 is the exact native 16-AA hGH(176-191) sequence and dissolves cleanly in standard BAC water; AOD-9604 adds an N-terminal Tyrosine (Tyr-hGH 177-191) and often requires pH-adjusted or acetic-acid-buffered reconstitution to prevent gelling.

Research Protocols

Summaries of published research. For educational purposes only.

Protocol NameSourceDoseFrequencyDurationRouteEvidenceLinkSave
Fasted Lipolytic SubQ Protocol
reported protocol
250 mcg – 500 mcg (0.25–0.5 mg)1–2x daily strictly fasted (AM before fasted cardio, optional PM 3+ hrs post-meal)8–12 weeksSubcutaneous injection (abdominal adipose)animal
Baseline & Mid-Cycle Biomarker Bloodwork Panel

Metabolic, Hepatic & Incretin Safety Biomarker Panel (HGH Fragment 176-191)

Quantify visceral fat mobilization, insulin resistance reversal, hepatic steatosis (MASH) clearance, and pancreatic/renal safety during metabolic protocols.

Draw fasted morning labs at Baseline (Day 0) and Mid-Cycle (Week 6–8)

HbA1c & Fasting Insulin (HOMA-IR)

Day 0 + Wk 6–8

Why track at baseline: Measures baseline hyperinsulinemia and 90-day glycemic load prior to incretin or lipolytic initiation.

Week 6–8 check: Track rapid drop in Fasting Insulin (often 30%–50% reduction by Week 6–8) and normalizing HbA1c.

ALT, AST & GGT Liver Enzymes

Day 0 + Wk 6–8

Why track at baseline: Dual/triple agonists (Retatrutide, Mazdutide, Pemvidutide) mobilize 65%–80% of intrahepatic triglycerides.

Week 6–8 check: Confirm progressive reduction in ALT/AST (<25 U/L) as hepatic steatosis clears.

ApoB, Triglycerides & Advanced Lipid Panel

Day 0 + Wk 6–8

Why track at baseline: Quantifies atherogenic particle burden and VLDL triglyceride export before weight loss.

Week 6–8 check: Expect 20%–40% triglyceride drop and significant ApoB improvement alongside visceral fat loss.

Serum Lipase, Amylase & eGFR / Cystatin C

Day 0 + Wk 6–8

Why track at baseline: Essential safety screen for subclinical pancreatic inflammation and hydration/renal filtration.

Week 6–8 check: Ensure Lipase stays within reference range and eGFR remains stable with adequate electrolyte hydration.

Test before and during your protocol: one baseline panel of 100+ Quest biomarkers covering the markers above, plus a mid-cycle retest. No doctor visit required.Code SPAMBASSADOR
Get baseline bloodwork at Superpower

Related Studies

1 Animal

Demonstrated that the C-terminal 176-191/177-191 domain of human growth hormone selectively reduces body fat accumulation and enhances fat oxidation in obese animal models without altering blood glucose or IGF-1.

Limitations: Human obesity trials conducted with the Tyr-modified analog (AOD-9604) showed modest standalone weight loss compared to modern GLP-1 agonists.

2000|Hormone Research / Endocrinology
PubMed

Community Outcomes

Community Data Coming Soon

Aggregate community outcomes will be displayed here once we have more reports. Be one of the first to share your experience!

Outcomes are self-reported and unverified. They represent individual experiences and may not reflect typical results.

Important Warnings

  • •Must be administered strictly fasted (at least 2–3 hours after and 45–60 minutes before carbohydrates/insulin spikes) or lipolytic signaling is blunted
  • •Prohibited at all times in tested sports by WADA under Section S2.2 (GH fragments)
  • •Not FDA approved; removed from FDA 503A Category 2 compounding list—available as an analytical research reference standard
Sourcing, Diagnostic Bloodwork & Telehealth Pathways

Where to get HGH Fragment 176-191, baseline labs & clinician oversight.

Compare all verified suppliers ↑
50% OFF AUTO-APPLIEDFrom $0.30/mg net

Ascension Peptides (US Vials)

MZ Biolabs & SafeCert COA-verified US domestic single vials with 50% off auto-applied for new customers.

MZ Biolabs COA (Grade A)Claim 50% Off
Verified Vial SuppliersGrade A COA

SwissChems & Limitless Biotech

Same-day US domestic lyophilized vials, oral capsules, and endotoxin-screened nasal sprays (15% off Limitless w/ code PEPTIDEPROTOCOLS).

LABS & 503A CLINICS$199/yr Labs · Rx Consult

Superpower Labs & 503A Telehealth

Bloodwork, not a vial store. Get a baseline panel (100+ Quest biomarkers: metabolic, lipids, hormones, inflammation, kidney/liver) before you start a peptide protocol, then retest mid-cycle to see what actually changed.

Code:SPAMBASSADOR
FREE 1-PAGE PDF CHEAT SHEET

Peptide Reconstitution & U-100 Syringe Cheat Sheet

Printable U-100 insulin syringe draw chart for 5mg–50mg vials, plus our weekly $/mg price-drop brief.

Unsubscribe anytime.Direct PDF Download

Related Peptides

Vendor vs vendor: price per mg

Head-to-head $/mg on shared compounds. Prices verified Nov 11, 2026.

Compound vs compound: BPC-157 vs TB-500 · Tirzepatide vs Semaglutide · Retatrutide vs Tirzepatide · Wolverine Blend vs GLOW Blend · Semax vs Selank · KLOW Blend vs GLOW Blend · MOTS-c vs SS-31 · Sermorelin vs Ipamorelin · Retatrutide vs Semaglutide · Tesamorelin vs Sermorelin · All compounds $/mg →

Common questions

How many peptides are in the database?

100 compound pages, each with dosing references, reconstitution math and price per mg where a verified vendor price exists.

Where can I compare peptide prices?

Each compound page shows verified $/mg by vendor; the vendor-vs-vendor pages above compare two vendors across their shared compounds.